Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Our AI ranks Cryo Cell International Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Cryo Cell International Inc is a small-cap company with a market capitalization of $36M. It ranks number 9 by market capitalization among the 13 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast.
For CCEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 24.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 24.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CCEL included.
Follow CCEL free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
| Metric | CCEL | Rank |
|---|---|---|
| Market Cap | $36M | 9/13 |
| Dividend Yield | 9.07% | – |
| EPS | $-0.23 | – |
| Revenue/Share | $3.86 | – |
| FCF/Share | $0.58 | – |
| Metric | CCEL | Rank |
|---|---|---|
| ROA | -3.1% | 6/9 |
| ROIC | 0.4% | 6/8 |
| Gross Margin | 78.5% | 1/6 |
| Operating Margin | 0.6% | 5/9 |
| Net Margin | -6.2% | 8/10 |
| EBT Margin | -6.1% | 7/10 |
| Tax Rate | -1.9% | – |
| Metric | CCEL | Rank |
|---|---|---|
| Current Ratio | 0.86x | 9/11 |
| Quick Ratio | 0.82x | 5/5 |
| Interest Coverage | 5.0x | 6/12 |
| Working Capital | -$2M | 10/11 |
| Metric | CCEL | Rank |
|---|---|---|
| Operating Cash Flow | $5M | 5/10 |
| Free Cash Flow | $5M | 5/7 |
| Capital Spending | -$270K | 2/7 |
| OCF Growth YoY | -22.6% | 5/6 |
| FCF Growth YoY | -24.8% | 4/5 |
| FCF/Sales | 14.9% | 1/7 |
| CapEx/Sales | 0.9% | 5/7 |
| Metric | CCEL | Rank |
|---|---|---|
| Asset Turnover | 0.50x | 6/9 |
| Receivables Turnover | 4.5x | 9/9 |
| Inventory Turnover | 12.5x | – |
| Fixed Assets Turnover | 1.5x | 6/8 |
| Days Sales Outstanding | 80 days | 1/9 |
| Days Inventory | 29 days | – |
| Payables Period | 132 days | 3/5 |
| Cash Conversion Cycle | -23 days | – |
| Metric | CCEL | Rank |
|---|---|---|
| Total Revenue | $31M | 7/10 |
| Operating Income | $190K | 5/9 |
| Net Income | -$2M | 7/10 |
| R&D Expense | $300K | 4/5 |
| SG&A Expense | $19M | 4/5 |
| Cost of Goods Sold | $7M | 5/7 |
| Metric | CCEL | Rank |
|---|---|---|
| Dividends Per Share | $0.40 | – |
| Shares Outstanding | 8M | – |
| EPS Growth | -2400.0% | 6/6 |
| Total Current Assets | $13M | 21.1% of assets |
| Cash & Short-term Investments | $1M | 2.3% of assets |
| Accounts Receivable | $7M | 11.0% of assets |
| Inventory | $530K | 0.9% of assets |
| Total Liabilities | $79M | |
| Short-term Debt | $13M | 20.7% of assets |
Companies classified under the same SEC industry code as Cryo Cell International Inc (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CCEL Cryo Cell International Inc | ▲ | $36M |
| FMS Fresenius Medical Care Ag | ▼ | $12.85B |
| DVA Davita Inc. | ▶ | $11.95B |
| SHC Sotera Health Co | ▼ | $5.11B |
| PGNY Progyny, Inc. | ▼ | $2.06B |
| AGL Agilon Health, Inc. | ▲ | $1.43B |
| VMD Viemed Healthcare, Inc. | ▼ | $361M |
| PARK Park Dental Partners, Inc. | ▲ | $91M |
| MRAI Marpai, Inc. | ▶ | $84M |
| PFHO Pacific Health Care Organization Inc | ▲ | $12M |
| MGRX Mangoceuticals, Inc. | ▲ | $7M |
| NIVF Newgenivf Group Ltd | ▼ | $2M |
| BRTX Biorestorative Therapies, Inc. | ▶ | $2M |
OLDSMAR, Fla., August 14, 2025--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company", "Cryo-Cell"), the world's first private cord blood bank to separate and store ...
OLDSMAR, Fla., April 28, 2026--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world's first private cord blood bank, has been granted renewed Foundation ...
Cryo-Cell International, Inc. reported earnings results for the third quarter and nine months ended August 31, 2026. For the third quarter, the company reported revenue was USD 7.82 million compared ...
Our AI ranks Cryo Cell International Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For CCEL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 24.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 24.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Cryo Cell International Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
13 issuers in our coverage, CCEL included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Fresenius Medical Care Ag (FMS), Davita Inc. (DVA), Sotera Health Co (SHC), Progyny, Inc. (PGNY), Agilon Health, Inc. (AGL), Viemed Healthcare, Inc. (VMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.